Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — Eyegate Pharmaceuticals — Investor Presentation (September 2018)
22 slides from Kiora Pharmaceuticals's investor presentation, Sep 5, 2018
Slide 1: Investor Presentation: Two Versatile Platforms Moving Towards Commercialization
NASDAQ: EYEG Investor Presentation Two Versatile Platforms Moving Towards Commercialization September 2018
Slide 2: Forward-Looking Statements
Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company’s OBG and EGP - 437 product candidates , for the timing and outcome of the Company’s clinical trial
Slide 3: Company Highlights
Two ophthalmic platform technologies - FDA market authorization filings expected in 2019 Two separate clinical studies initiated for the OBG eye drop: PRK and PE (e.g. dry eye) EGP - 437’s Phase 3 Uveitis trial misses primary endpoint, data under review to assess strategic options OBG is the first a
Slide 4: Two Proprietary Technology Platforms
Two Proprietary Technology Platforms • Platform based on uniquely modified hyaluronic acid that is well known for its healing properties • EyeGate Ocular Bandage Gel (OBG), a topically applied eye drop, is first product developed from this platform • Separate trials underway to assess treatments to:
Slide 5: Anticipated Inflection Points
Anticipated Inflection Points 5 Program Disease Area Q3 2018 Q4 2018 OBG Eye Drop Cross - linked Hyaluronic Acid Large Corneal Wounds: Photorefractive Keratectomy (PRK) 2 nd Pilot Study Initiated 2 nd Pilot Study Top - Line Data Punctate Epitheliopathies (PE): e.g. Dry Eye Pilot Study Initiated Pilo
Slide 6: CMHA-S Platform Ocular Bandage Gel (OBG) Eye Drop
CMHA - S Platform Ocular Bandage Gel (OBG) Eye Drop
Slide 7: OBG: A Differentiated Product on a Rapid Path to Approval
7 OBG: A Differentiated Product on a Rapid Path to Approval Proprietary Formulation of a Known and Trusted Substance Creates a Unique and Differentiated Product » Following a medical device pathway, filing expected in 2019 » Unique crosslinked HA produces a preservative - free, high concentration ey
Slide 8: Hyaluronic Acid (HA)
8 Hyaluronic Acid (HA) HA is a Naturally Occurring Molecule that Possesses Beneficial Properties Hyaluronic Acid » Non - immunogenic: does not illicit an immune response » Binds up to 1,000 times its volume in water weight providing hydration and lubrication ideal for the ocular surface » Contribute
Slide 9: Ocular Bandage Gel (OBG) Eye Drop Differentiation
Ocular Bandage Gel (OBG) Eye Drop OBG is Differentiated by its Unique Cross - Linked, High Concentration Formulation of HA The unique cross - linked HA creates a 3D structure that stabilizes the molecule providing: Hyaluronic Acid Hyaluronic Acid Hyaluronic Acid Cross - Link 9 » A scaffolding matrix
Slide 10: OBG Efficacy Demonstrated in Animal Conditions
10 » A clear, viscous, preservative - free eyedrop containing a high concentration (0.75%) of crosslinked hyaluronic acid (CMHA - S) » A long - acting lubricant that protects the corneal surface to promote healing and reduce staining associated with Punctate Epitheliopathies in dry eye patients » De
Slide 11: Broad Market Opportunity
PE (non - dry eye) ~45.0 million Epithelial injury (exposure) ~16.0 million Ocular trauma ~1.8 million Surgery ~1.0 million Broad Market Opportunity 11 Wounds: Surgery • Refractive surgeries (PRK) • LASIK • Collagen cross - linking Wounds: Trauma • Injuries / Abrasions • Chemical burns • Difficult t
Slide 12: Increasing Prevalence of Dry Eye Disease with Favorable Economics
12 Increasing Prevalence of Dry Eye Disease with Favorable Economics 1. Gayton JL. Clin Ophthalmol . 2009;3:405 - 12.; 2. Report of the international dry eye workshop (DEWS). Ocul Surf. 2007;5(2):65 - 204.; 3. Allergan Dry Eye Survey, American Optometric Association, November 6, 2011. Dry Eye Diseas
Slide 13: Positive Clinical Trial Results
Positive Clinical Trial Results 13 Completed First Human Clinical Trial in PRK Patients Healed Wound on Day 3 Day 1 Day 3 Number of Subjects Per Arm Number Percent Horizontal* Vertical* Horizontal Vertical Arm 1 Ocular Bandage Gel 12 10 83.3% 4.1 4.5 0.1 0.2 Arm 2 Ocular Bandage Gel + Bandage Contac
Slide 14: Ongoing Clinical Trials for Management of Corneal Injury
Ongoing Clinical Trials Currently Enrolling for Two Studies for Management of Corneal Injury 14 Additional study for patients that have undergone bilateral Photorefractive Keratectomy (PRK) • Objective is to demonstrate re - epithelialization of large corneal epithelial defects • 45 subjects (3 arms
Slide 15: Iontophoresis Platform
Iontophoresis Platform EyeGate® II Delivery System and EGP - 437
Slide 16: EyeGate II Delivery System and EGP-437
EyeGate® II Delivery System and EGP - 437 16 A Non - Invasive Method of Propelling Charged Active Compounds into Ocular Tissues EGP - 437 , a reformulated corticosteroid, Dexamethasone Sodium Phosphate is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system
Slide 17: A Highly Differentiated Product
A Highly Differentiated Product 17 The current Standard of Care for both Anterior Uveitis and Cataract Surgery are corticosteroid eye drops The EyeGate®II Delivery System Combined with EGP - 437 Significantly Decreases the Patient Burden by Reducing Treatment Applications by up to 98% The EyeGate® I
Slide 18: Exclusive Licensing Agreement with Bausch Health
Exclusive Licensing Agreement with Bausch Health (Formerly Valeant Pharmaceuticals) 18 Worldwide License to Manufacture, Sell, Distribute, and Commercialize EGP - 437 with the EyeGate® II Delivery System for Uveitis and Post - Operative Ocular Inflammation and Pain $136.5 million in potential paymen
Slide 19: Clinical Data Results
19 EGP - 437 Clinical Data Results Inflammation Post Cataract Surgery Phase 2 Clinical Trial Double - masked, placebo - controlled, two - arms, 101 subjects 5.9% 13.7% 27.5% 43.1% 52.9% 4% 10% 24% 32% 36% Day 1 Day 4 Day 7 Day 14 Day 28 EGP-437 (N=51) Vehicle (N=50) Proportion with Total Cell Cleari
Slide 20: The Future of Ocular Drug Delivery: Drug-Embedded Contact Lens
The Future of Ocular Drug Delivery: Drug - Embedded Contact Lens 20 Potential to Revolutionize the Treatment of Chronic Retinal Conditions at Home by Significantly Reducing or Eliminating Intravitreal Injections and Frequent Office Visits Two Layer Lens Layer 1 : Sits on eye surface with loaded drug
Slide 21: Company Highlights
Two ophthalmic platform technologies - FDA market authorization filings expected in 2019 Two separate clinical studies initiated for the OBG eye drop: PRK and PE (e.g. dry eye) EGP - 437’s Phase 3 Uveitis trial misses primary endpoint, data under review to assess strategic options OBG is the first a
Slide 22: Thank You / Contact Us
Thank You NASDAQ: EYEG Contact Us Joseph Green Edison Advisors Investor Relations Tel: (646) 653 - 7030 E - mail: jgreen@edisongroup.com
Eyegate Pharmaceuticals — Investor Presentation (September 2018) on 6ix